Abstract
In this issue of The Lancet, Anthony Swerdlow and colleagues report findings on cancer risk in a cohort of 1848 patients who were deficient in growth hormone and treated with human-pituitary growth hormone at young ages between 1959 and 1985. These individuals were followed up for cancer incidence to December, 1995, and for mortality to December, 2000. Compared with cancer rates in the general population, rates in treated patients showed significantly increased risks of mortality from cancer overall, particularly from colorectal cancer and Hodgkin's disease. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort studyAlthough based on small numbers, the risk of colorectal cancer is of some concern and further investigation in other cohorts is needed. We have no evidence as to whether growth hormone in modern dosage regimens is associated with an increased risk of colorectal cancer. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
